Primary Membranous Nephropathy (PMN) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Primary Membranous Nephropathy (PMN) Emerging Therapy and TPP Insights

Thelansis's "Primary Membranous Nephropathy (PMN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Primary Membranous Nephropathy (PMN) Overview

Primary Membranous Nephropathy (PMN) is a specific, autoimmune-mediated glomerular disease and a leading cause of nephrotic syndrome in non-diabetic adults. Clinically, it presents with massive proteinuria (>3.5 g/day), peripheral edema, hypoalbuminemia, hyperlipidemia, and an increased risk of thromboembolic complications, including renal vein thrombosis.

The pathophysiology is characterized by subepithelial deposition of IgG4 autoantibodies and complement complexes (C5b-9 membrane attack complex) along the glomerular basement membrane, leading to podocyte injury and disruption of the filtration barrier.

Modern classification of PMN is based on its molecular drivers. Approximately 70-80% of cases are associated with anti-PLA2R (M-type phospholipase A2 receptor) antibodies, while ~1-5% are linked to THSD7A antibodies. This molecular understanding has significantly transformed disease management, enabling non-invasive diagnosis through serological testing and the use of antibody titers for disease monitoring and risk stratification.

PMN predominantly affects adults, with peak incidence in middle-aged and older populations. Diagnosis is supported by serology and, where required, kidney biopsy.

Treatment strategies include supportive therapy (ACE inhibitors, ARBs, statins, diuretics) and immunosuppressive regimens, including corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Notably, B-cell depleting therapies such as rituximab have become central to modern management, enabling targeted immunological remission.

Despite advances, PMN remains a chronic, relapsing condition, with ongoing risk of progression to chronic kidney disease (CKD) or end-stage renal disease (ESRD), driving continued need for novel targeted therapies.

Key Highlights

• The diagnosed prevalent PMN population in the United States is estimated at 86,410 in 2025, increasing to 97,845 by 2035, reflecting steady disease burden growth.
• The incident diagnosed population grows from 3,297 cases in 2025 to 3,546 cases by 2035, indicating gradual increase in diagnosis rates.
• PMN shows a strong female predominance, with 34,996 female vs 51,414 male cases in 2025, widening further by 2035 (39,627 females vs 58,218 males).
• The average age of patients is 48 years, with the highest disease burden concentrated in >=55 years age group.
• The disease is chronic and progressive, with a significant proportion of patients requiring long-term immunosuppressive therapy, contributing to sustained treatment demand.

Market Overview

• The PMN treatment market is valued at $622M in 2025, projected to reach $3.18Bn by 2035, representing a robust CAGR of 17.8% over the forecast period.
• Early-stage market (2025-2027) is dominated by conventional therapies, including: ACE inhibitors / ARBs, Corticosteroids (prednisone, methylprednisolone), Immunosuppressants (cyclosporine, tacrolimus, MMF), Rituximab and IVIG
• By 2035, novel biologics and targeted therapies dominate the market, accounting for the majority of revenue share, significantly shifting the treatment paradigm.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Excyte Biopharma Ltd
• Climb Bio, Inc.
• Cerium Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• argenx
• BioRay Pharmaceutical Co., Ltd.
• Shanghai JMT-Bio Inc.
• Beijing Mabworks Biotech Co., Ltd.
• Biogen
• Guangdong Hengrui Pharmaceutical Co., Ltd
• BeOne Medicines
• Hoffmann-La Roche
• Everest Medicines (China) Co.,Ltd.
• Nkarta, Inc.
• Walden Biosciences
• Apellis Pharmaceuticals, Inc.
• Alpine Immune Sciences, Inc.
• Vera Therapeutics, Inc.
• Reistone Biopharma Company Limited